A production delay of the FluMist flu vaccine has U.K. pharmaceutical giant AstraZeneca scrambling to alleviate shortages at doctors offices this flu season.
Only 5 million doses of the vaccine made by Gaithersburg-based MedImmune, the biologics research and development arm of AstraZeneca PLC (NYSE: AZN), has been delivered so far this season. AstraZeneca originally said it planned to distribute 15 million doses.
{iframe}http://www.bizjournals.com/washington/news/2015/10/21/no-flumist-at-the-doctors-office-medimmune-product.html?ana=e_du_pap&s=article_du&ed=2015-10-21&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1445548352{/iframe}